KR20130122958A - 망막의 질환을 치료하기 위한 방법 - Google Patents

망막의 질환을 치료하기 위한 방법 Download PDF

Info

Publication number
KR20130122958A
KR20130122958A KR20137017036A KR20137017036A KR20130122958A KR 20130122958 A KR20130122958 A KR 20130122958A KR 20137017036 A KR20137017036 A KR 20137017036A KR 20137017036 A KR20137017036 A KR 20137017036A KR 20130122958 A KR20130122958 A KR 20130122958A
Authority
KR
South Korea
Prior art keywords
retinal
disease
blue light
retina
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20137017036A
Other languages
English (en)
Korean (ko)
Inventor
지오티르모이 엑스. 쿠사리
쉴라 엑스. 조우
밍팅 티엔
에드윈 유. 패딜로
산드히야 에스. 라오
다니엘 더블유. 길
래리 에이. 휠러
Original Assignee
알러간, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알러간, 인코포레이티드 filed Critical 알러간, 인코포레이티드
Publication of KR20130122958A publication Critical patent/KR20130122958A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR20137017036A 2010-12-03 2011-11-18 망막의 질환을 치료하기 위한 방법 Ceased KR20130122958A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41966010P 2010-12-03 2010-12-03
US61/419,660 2010-12-03
PCT/US2011/061370 WO2012074788A1 (en) 2010-12-03 2011-11-18 Methods for treating diseases of the retina

Publications (1)

Publication Number Publication Date
KR20130122958A true KR20130122958A (ko) 2013-11-11

Family

ID=45507856

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20137017036A Ceased KR20130122958A (ko) 2010-12-03 2011-11-18 망막의 질환을 치료하기 위한 방법

Country Status (10)

Country Link
US (2) US9018202B2 (https=)
EP (1) EP2646034A1 (https=)
JP (1) JP2013544838A (https=)
KR (1) KR20130122958A (https=)
CN (1) CN103327981A (https=)
AU (1) AU2011336976A1 (https=)
BR (1) BR112013013636A2 (https=)
CA (1) CA2819616A1 (https=)
RU (1) RU2013129748A (https=)
WO (1) WO2012074788A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752593B2 (en) 2018-12-28 2020-08-25 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
JP6864327B2 (ja) 2017-07-06 2021-04-28 山田　健一 脂質過酸化誘発性疾患の治療薬およびそのスクリーニング方法
US10807973B2 (en) 2018-12-28 2020-10-20 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
EP3919052A4 (en) * 2019-01-09 2022-10-05 Fuso Pharmaceutical Industries, Ltd. Pharmaceutical composition for intraocular or oral administration for treatment of retinal diseases
US20250170143A1 (en) * 2022-04-14 2025-05-29 Mayo Foundation For Medical Education And Research Methods of treating ocular fibrotic pathologies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1004520A1 (en) 1992-05-13 1998-11-27 Novartis Ag Ophthalmic compositions containing a cyclosporin
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US5631250A (en) 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
US5744468A (en) * 1996-10-23 1998-04-28 Tong-Ho Lin Hypotensive intraocular pressure activity of clozapine and sulpiride
JPH10175865A (ja) * 1996-12-11 1998-06-30 Towa Rin 抗眼圧活性製剤
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
JP2002530340A (ja) * 1998-11-23 2002-09-17 セプラコール， インク． オランザピン−ｎ−オキサイドを含む医薬組成物
DE10206941A1 (de) 2002-02-19 2003-09-25 Goetz Nowak Neue Arzneimittel
JP2006515628A (ja) * 2003-01-23 2006-06-01 アカディア ファーマシューティカルズ，インコーポレーテッド ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用
WO2004103263A2 (en) 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050277584A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US20060035887A1 (en) 2004-07-02 2006-02-16 Dr. Reddy's Laboratories Limited Process for preparing olanzapine
AU2005271513A1 (en) * 2004-08-05 2006-02-16 Acadia Pharmaceuticals Inc. Use of N-desmethylclozapine to treat human neuropsychiatric disease
CN101437478A (zh) * 2004-10-04 2009-05-20 Qlt美国有限公司 聚合送递制剂的眼部送递
MX2007003789A (es) 2004-10-04 2007-07-20 Qlt Usa Inc Suministro ocular de formulaciones polimericas para suministro.
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
WO2008111497A1 (ja) * 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
CN101711236B (zh) * 2007-04-12 2012-10-31 Nsab神经研究瑞典公司分公司 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物

Also Published As

Publication number Publication date
CN103327981A (zh) 2013-09-25
US9018202B2 (en) 2015-04-28
CA2819616A1 (en) 2012-06-07
AU2011336976A1 (en) 2013-07-11
JP2013544838A (ja) 2013-12-19
US9561234B2 (en) 2017-02-07
BR112013013636A2 (pt) 2016-11-08
EP2646034A1 (en) 2013-10-09
RU2013129748A (ru) 2015-01-10
WO2012074788A1 (en) 2012-06-07
US20150290215A1 (en) 2015-10-15
US20120142675A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
Oharazawa et al. Protection of the retina by rapid diffusion of hydrogen: administration of hydrogen-loaded eye drops in retinal ischemia–reperfusion injury
ES2494791T3 (es) Uso de rapamicina para el tratamiento o prevención de la degeneración macular asociada a la edad
JP6060168B2 (ja) レバミピドと涙液保持作用を有する薬剤からなる前眼部疾患治療剤
US9561234B2 (en) Methods for treating diseases of the retina
JP5801324B2 (ja) 緑内障及び高眼圧症の治療のためのシチコリン
AU2024200866A1 (en) Compositions and methods for treating ocular pathologies
US9254287B2 (en) Therapeutic formulation and methods of treatment
JP7615139B2 (ja) 萎縮型加齢黄斑変性（ａｍｄ）又は萎縮型ａｍｄに続発する地図状委縮の治療用抗ｃ５剤
CN107249577A (zh) 用于治疗青光眼的组合物和方法
EP4141018A1 (en) Peptide fg and its use in preparation of drugs for treating and preventing ocular fundus vascular diseases
US20150253308A1 (en) Compositions and methods of treating glaucoma
US20130316983A1 (en) Drug screening method, compositions and methods of treating glaucoma
US6214819B1 (en) Method for treating ocular neovascular diseases
EP4141019A1 (en) Peptide fh and its use in preparation of drugs for treating and preventing ocular fundus vascular diseases
US20140179741A1 (en) Use of chelators of divalent cations to promote nerve regeneration
CN116650461A (zh) 咖啡酸苯乙酯滴及其眼液在制备治疗糖尿病视网膜病变药物中的应用
Bastola et al. SPG302 protects retinal ganglion cells and preserves visual function by preserving synaptic activity in a mouse model of glaucoma
CA2888984A1 (en) Methods for treating eye disorders
US20090082455A1 (en) Therapeutic agent for ophthalmic disease
US9682062B2 (en) Pharmaceutical compositions and method for inhibiting angiogenesis
KR101587609B1 (ko) 베타-사이클로덱스트린을 포함하는 신규한 안약 제형
WO2026078034A1 (en) Sitagliptin for use in retinal diseases with neovascularization
JP2023547412A (ja) 眼疾患の治療
CN118286229A (zh) (+)-jq1在制备治疗增生性视网膜病变的药物中的应用
CN101759741B (zh) 一种化合物及其在制备治疗血管新生的药物中的应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130628

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20161115

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171026

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180103

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20171026

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I